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Background: Improvement in ultrasound imaging has led to the identification of subtle non-structural markers
during the 18 – 20 week fetal anomaly scan, such as echogenic bowel, mild cerebral ventriculomegaly, renal
pelvicalyceal dilatation, and nuchal thickening. These markers are estimated to occur in between 0.6% and 4.3% of
pregnancies. Their clinical significance, for pregnancy outcomes or childhood morbidity, is largely unknown. The
aim of this study is to estimate the prevalence of seven markers in the general obstetric population and establish a
cohort of children for longer terms follow-up to assess the clinical significance of these markers.
Methods/Design: All women receiving antenatal care within six of seven Welsh Health Boards who had an 18 to
20 week ultrasound scan in Welsh NHS Trusts between July 2008 and March 2011 were eligible for inclusion. Data
were collected on seven markers (echogenic bowel, cerebral ventriculomegaly, renal pelvicalyceal dilatation, nuchal
thickening, cardiac echogenic foci, choroid plexus cysts, and short femur) at the time of 18 – 20 week fetal anomaly
scan. Ultrasound records were linked to routinely collected data on pregnancy outcomes (work completed during
2012 and 2013). Images were stored and reviewed by an expert panel.
The prevalence of each marker (reported and validated) will be estimated. A projected sample size of 23,000 will
allow the prevalence of each marker to be estimated with the following precision: a marker with 0.50% prevalence
to within 0.10%; a marker with 1.00% prevalence to within 0.13%; and a marker with 4.50% prevalence to within
0.27%. The relative risk of major congenital abnormalities, stillbirths, pre-term birth and small for gestational age,
given the presence of a validated marker, will be reported.
Discussion: This is a large, prospective study designed to estimate the prevalence of markers in a population-based
cohort of pregnant women and to investigate associations with adverse pregnancy outcomes. The study will also
establish a cohort of children that can be followed-up to explore associations between specific markers and longer-term
health and social outcomes.
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All pregnant women in the UK are offered an ultrasound
scan to screen for structural anomalies between 18 and
20 weeks of pregnancy as part of their routine antenatal
care [1]. Some structural abnormalities detected at this
examination may be associated with an increased risk of
chromosomal abnormalities. The diagnostic test for con-
firming this requires analysis of fetal genetic material
that may be obtained by invasive procedures such as
chorionic villi sampling or an amniocentesis which carry
a procedure-related miscarriage risk of at least 1% [2].
In addition to significant structural abnormalities, ultra-
sound imaging has led to the identification of more subtle
markers such as echogenic bowel, mild cerebral ventricu-
lomegaly, renal pelvicalyceal dilatation, nuchal thickening,
cardiac echogenic foci (golf balls), choroid plexus cysts,
and short femur. In this protocol paper we refer to these
collectively as markers. Reports of the prevalence of
markers detected on antenatal scans vary, with one review
suggesting that the range of the overall prevalence of all
markers was 0.6% to 4.3% [3]. Isolated cardiac echogenic
foci have been reported in 0.5%-4.9% of scans [4,5],
choroid plexus cysts in 0.6% - 2.1% [6], mild pelvicaly-
ceal dilatation in 0.3% - 4.5% [7,8] and echogenic bowel
in 0.2% – 1.4% [7,9]. Some of this variation was attrib-
uted to heterogeneity in the populations that have been
studied. Many studies were carried out in tertiary or
specialist institutions that manage a large number of
high-risk pregnancies, while in other studies there was
a lack of information about the characteristics of the
populations that were studied. Variation may also result
from the use of different definitions of the markers.
The clinical significance of these markers is unclear
[3]. For example, there have been reports that echogenic
bowel may be associated with cystic fibrosis [9,10] and ad-
verse pregnancy outcomes such as intra-uterine growth
restriction and stillbirths [11,12], particularly in high-risk
pregnancies. However, there is uncertainty about their
significance in low-risk pregnancies (i.e. those who do
not have risk factors for chromosomal abnormalities or
other pregnancy complications). There is also uncer-
tainty among healthcare professionals about the best
practice in clinical management of pregnancies where
these markers are identified at the fetal anomaly scan
[13]. UK-wide data has suggested that there is variation
between hospitals in their clinical management of
markers and in the information and quality of care
given to women [14,15].
The reporting of ultrasound findings of uncertain sig-
nificance can cause unresolved maternal anxiety [16]
and exposure to the risks associated with invasive diag-
nostic tests, although new standards for the performance
of amniocentesis and chorionic villus sampling in Wales
give clear guidance on appropriate indications for theseprocedures [17]. For some of these markers, it is not
known whether there are long-term adverse health out-
comes in children [3]. Questions that remain unanswered
include: whether cardiac echogenic foci are associated
with future development of cardiac abnormalities in child-
hood; whether mild cerebral ventriculomegaly (defined as
a ventricular atrial diameter at any gestation of 10 mm to
12 mm) is associated with neuro-developmental delay and
poorer educational outcomes; or whether pelvicalyceal
dilatation is associated with postnatal uropathies or recur-
rent urinary tract infections in childhood.
We designed a population-based study to investigate
the prevalence of markers and their associations with
adverse pregnancy outcomes and longer-term health and
social outcomes in children. The study objectives are:
1. To estimate the prevalence of individual markers at
the 18 to 20 week anomaly scan in an unselected
population of pregnant women attending for routine
antenatal care in Wales;
2. To assess inter- and intra-sonographer variability in
the detection of markers;
3. To investigate associations between the presence of
markers and adverse pregnancy outcomes
(major congenital abnormality, stillbirth, pre-term
birth and small for gestational age);
4. To establish a cohort of children that can be
followed-up to investigate associations between
specific markers and longer-term health outcomes.
Methods/Design
Research design and setting
This is a population-based cohort study embedded
within the routine antenatal services offered to pregnant
women by NHS Wales. The population of Wales is ap-
proximately 3 million people, of whom approximately
20% are women of reproductive age [18]. All pregnant
women have access to NHS maternity care, with almost
universal uptake. Minimum standards for maternity care
(including guidance on performing ultrasound scans) are
recommended by the National Institute for Health and
Care Excellence (NICE) and include at least ten ante-
natal check-ups for women expecting their first baby [1].
Wales is in a unique position to carry out this study be-
cause of the way in which healthcare data are routinely
collected and can be electronically record-linked. First,
an electronic information system for radiological data
storage and reporting (Radiology Information Service 2
or RadIS2) was recently implemented in Welsh hospitals.
Second, there are ongoing high-quality population-based
registers for child health, including measures of pregnancy
outcome such as gestation and weight at birth, congenital
anomalies, stillbirths, neonatal and infant deaths recorded
for all babies born in Wales. All of these systems
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to link mother and baby across these routinely collected
child health datasets. This provided a unique opportunity
to collect standardised information on markers in a cohort
of pregnant women and link these data to pregnancy and
child health outcomes in their babies.
Ethical approval
Ethical approval was given by the Multicentre Research Ethics
Committee (MREC) for Wales (reference 08/MRE09/17).
Participants and recruitment
Inclusion and exclusion criteria
All pregnant women receiving antenatal care within six of
seven Welsh Health Boards who had an 18 to 20 week
ultrasound scan in Welsh NHS Trusts between July 2008
and March 2011 were eligible for inclusion. The seventh
Board was excluded as some of their population received
antenatal ultrasound scans from hospitals outside Wales
that did not use the RadIS2 system. Women were excluded
if they were unable to give written informed consent.
Sample size calculations
Given the number of births in each Health Board and
the planned phased introduction schedule for RadIS2
(which varied across Health Boards), it was anticipatedTable 1 Definition of markers included in the study
1 Echogenic bowel (EB) Areas of increased echogenicity in the fetal
or multiple loops of bowel may be identifie
intraluminal echogenicity or occasionally ec
2 Mild to moderate
ventriculomegaly (VM)
Mild to moderate ventriculomegaly is a ven
from 10 mm to 15 mm. Measurements are
view at the level of the glomus of the choro
the inner margins of the echogenic ventricu
3 Pelvicalyceal dilatation (PCD) Fluid filled dilatation of the renal pelvis mea
anterior-posterior (AP) diameter of 5 mm or
inner AP margins of the pelvic wall). This m
4 Nuchal thickening (NT) Thickening of the skin and the subcutaneous
fetal neck. This is best viewed in a modified b
the cavum septum pellucidum and cerebellu
between the skin and occipital bone at the p
callipers placed on the outer edge of the bon
measurement of 6 mm or greater was consid
20 + 6 weeks gestation.
5 Choroid plexus cysts (CPC) Small sonographically discrete fluid-filled sp
and seen on scan as black echo-free areas.
bilateral.
6 Echogenic cardiac foci (ECF) Echogenic area on the papillary muscle of e
atrioventricular valves.
7 Short femur (SF) Femur length which is below two standard
age when measured with the shaft of the fe
must be taken to ensure that the entire dia
epiphyseal cartilages are visible they were n
assumed that the remainder of the skeletonthat approximately 39,000 pregnant women would be
eligible for recruitment during the study period. Assum-
ing that 75% of these women would agree to participate
(29,000) and that complete ultrasound and outcome data
would be available for 80% of pregnancies, the study
would have a projected sample size of 23,000.
A broad range of estimates for the prevalence of
markers has been reported in previous studies (Table 1).
Using several values from within this range, we per-
formed sample size calculations to estimate i) the preci-
sion with which we could measure marker prevalence,
and ii) the risk ratios that could be detected when exam-
ining the association between a marker and an adverse
pregnancy outcome with 80% power at a 5% significance
level. Data from 23,000 pregnancies would allow the preva-
lence of individual markers to be estimated with the fol-
lowing precision: a marker with 0.50% prevalence to within
0.10%; a marker with 1.00% prevalence to within 0.13%;
and a marker with 4.50% prevalence to within 0.27%. The
following sample size calculations are based on 80% power
and a 5% Type 1 error rate. With 23,000 pregnancies and a
marker prevalence of 0.5%, the sample size would be ad-
equate to detect a 7-fold increase in an adverse pregnancy
outcome which had a baseline prevalence of 1%, or a 2.75-
fold increase in an adverse pregnancy outcome with a
prevalence of 5%. With a marker prevalence of 1%, thebowel that are as bright as bone. Single
d and it may be noted to be solid
hogenicity of the walls only (tram line).
Reported prevalence at fetal
anomaly scan from previous
studies [7,9]: 0.2 – 1.4%
tricular atrial diameter, at any gestation,
obtained from a transventricular axial
id plexus. The callipers were placed on
lar wall.
Reported prevalence at fetal
anomaly scan from previous
studies [19]: 0.1%
sured on axial section with an
greater (callipers to be placed on the
ay be unilateral or bilateral.
Reported prevalence at fetal
anomaly scan from previous
studies [7,8]: 0.3 – 4.5%
tissues on the posterior aspect of the
iparietal diameter (BPD) view to include
m. Assessed by measuring the distance
osterior aspect of the neck with the
e and the outer edge of the skin. A
ered to indicate thickening before
Reported prevalence at fetal
anomaly scan from previous
studies [20,21]: 0.4 – 0.6%
aces≥ 5 mm within the choroid plexus
May be single, multiple, unilateral or
Reported prevalence at fetal
anomaly scan from previous
studies [6]: 0.6 – 2.1%
ither (usually left) or both of the Reported prevalence at fetal
anomaly scan from previous
studies [4,5]: 0.5 – 4.9%
deviations (3rd centile) for gestational
mur parallel to the transducer. Care
physis of the femur is measured. If the
ot included in the measurement. It is
is normal.
Reported prevalence at fetal
anomaly scan from previous
studies [7]: < 5%
Table 2 Data items collected for the study and source
Hurt et al. BMC Pregnancy and Childbirth 2014, 14:164 Page 4 of 7
http://www.biomedcentral.com/1471-2393/14/164sample size would be adequate to detect a 5-fold increase
in an adverse pregnancy outcome which had a prevalence
of 1%, or a 2-fold increase in an adverse pregnancy out-
come with a prevalence of 5%. With a marker prevalence
of 4.50%, the sample size would be adequate to detect with
a 2.3-fold increase in an adverse pregnancy outcome which
had a prevalence of 1%, or a 1.5-fold increase in an adverse
pregnancy outcome with a prevalence of 5%.
Recruitment
Figure 1 shows the flow chart for recruitment, data col-
lection and data linkage. Recruitment of pregnant women
to the study started in July 2008 and ended in March
2011, with a phased roll-out to match the planned phased
roll out of RadIS2 across Wales. A study information leaf-
let was included in the antenatal screening information
pack given to pregnant women as early as possible in the
pregnancy (at approximately eight to ten weeks of gesta-
tion). Women were given verbal information about the
study and the opportunity to ask questions and obtain
clarification about participation during their first antenatal
visit with a healthcare professional (usually conducted by
a community midwife between eight and twelve weeks of
pregnancy). At this appointment, consent was obtained to:
1. Record the presence of markers;
2. Obtain antenatal Down’s syndrome screening results
and cytogenetic results (if undertaken);Figure 1 Flow chart of recruitment, data collection and data
linkage.3. Use NHS numbers of the mother and her baby to
link ultrasound data with data on pregnancy and
health outcomes from the National Community
Child Health Database (NCCHD), All Wales
Perinatal Survey (AWPS), Congenital Anomaly
Register and Information Service (CARIS), and
newborn bloodspot tests; and,
4. Make future contact to obtain follow-up data on
their baby.
Study stickers were placed on the front of the ante-
natal maternity hand-held notes of all women who had
consented to participate to aid in the identification of
these women at future contacts with health profes-
sionals. Stickers were also placed on the request card for
the 18 to 20 week ultrasound scan in some sites. The
consent form and the patient information leaflet are
shown in Additional file 1 and Additional file 2.
Baseline data collection
The specific data items collected and the sources of data
are shown in Table 2. A self-administered questionnaire
following recruitment was used to collect baseline data
on socio-demographics, smoking and alcohol use, and
obstetric history. The postcode was used to assign
women into a deprivation quintile using the WelshData item Source
Data collected specifically for this study
Name, date of birth, address, postcode Baseline questionnaire,
RADIS2
NHS number
Employment status Baseline questionnaire
Smoking and alcohol use
Obstetric history
Weight RADIS2 or paper proforma
Height
BMI
Presence or absence of the following
markers:
Cardiac Echogenic Foci, Choroid Plexus
Cyst, Echogenic Bowel, Mild
Ventriculomegaly, Nuchal Thickening,
Short Femur, Pelvicalyceal Dilatation
Routinely collected data
Pregnancy outcome, live birth, stillbirth,
gestation at birth, birth weight, neonatal
death, infant death
NCCHD and AWPS
Presence of any structural abnormality,
congenital malformation or cystic fibrosis
CARIS
Cytogenetic information Cardiff and Vale Cytogenetic
laboratory, CARIS
Down’s syndrome risk NHS Biochemistry laboratory
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except one, women were given the questionnaire by a
support worker, receptionist or sonographer to complete
while waiting for their anomaly scan. Once completed,
the questionnaires were placed in a box in the ultra-
sound department. Due to logistic reasons, one Health
Board distributed and collected the questionnaires when
the women attended their first hospital visit.
Data collection on markers
The definitions of the seven markers included in the
study are shown in Table 1. The current practice in
Wales is to routinely report four of these (echogenic
bowel, mild to moderate ventriculomegaly, renal pelvica-
lyceal dilatation, and nuchal thickening). Data on the
other three markers (choroid plexus cysts, echogenic
cardiac foci, and short femur) were collected specifically
for this study; these were not recorded on the clinical re-
port and the woman was not informed of the finding
given that these markers would not be reported in usual
care. This was explained to the women as part of the
consent process.
The presence or absence of markers was recorded in
the RadIS2 system at the time of the 18 to 20 week scan.
An additional reporting screen was added on to this sys-
tem to enable rapid and accurate data collection for the
study. Sonographers were requested to access this screen
during the scans of all women who had consented to
participate. RadIS2 implementation was delayed in three
Health Boards. Alternative data reporting arrangements
using paper forms were implemented at these locations.
Quality assurance of marker reporting
Before recruitment began, the sonographers in each
Health Board (n = 140) attended an introductory session
and were provided with a ‘Reference Guide for Sonogra-
phers’ which included the criteria for each marker as set
out for this study. After this session, they were asked to
complete a paper-based questionnaire to assess (i) com-
pliance with the study protocol for the measurement of
markers, (ii) agreement between sonographers and (iii)
intra-sonographer agreement in reporting markers (by
asking a sample of sonographers to complete the ques-
tionnaire a second time). The data generated were used
to assess the level of compliance to the study protocol
for the reporting of markers. These training and educa-
tional issues were discussed with superintendent sono-
graphers in each Health Board who then provided
additional training for their sonographers to address any
gaps in knowledge identified.
An expert panel, consisting of radiologists and super-
intendent sonographers was established to review all
anomaly scan images in which a marker had been re-
ported (where images were available for review), toconfirm the presence of the reported marker and iden-
tify any false positives. A review of all scan data by the
expert panel to assess for false negative reports was not
possible due to the substantial number of scans. How-
ever, the panel did review the scan images for all still-
births, chromosomal abnormalities reported (Down’s
and Edward’s syndrome) and cases of cystic fibrosis, to
ascertain whether or not there were any markers visible
in those scans that were not reported initially.
Definitions of adverse pregnancy outcomes
Major congenital abnormalities were as defined in Chapter
XVII of the tenth revision of the International Statistical
Classification of Diseases and Related Health Problems [23]
and reported to the European Surveillance of Congenital
Anomalies (EUROCAT), and were ascertained from cyto-
genetic results following amniocentesis or a report to
CARIS at up to 1 year after the birth. Stillbirths are defined
as the in-utero death of a baby after 24 completed weeks’
gestation. A preterm birth is defined as a birth before
37 weeks’ gestation, and small for gestational age is defined
as below the 3rd centile for birth weight appropriate for ges-
tational age, stratified by sex.
Data linkage
We used the NHS numbers of study participants to link the
ultrasound scan data with routinely-collected data on preg-
nancy and health outcomes from NCCHD, AWPS, CARIS,
All Wales Medical Genetics Service, Cytogenetics Depart-
ment and the Down’s screening service (University Hospital
of Wales, Department of Medical Biochemistry and Immun-
ology). The extraction of outcome data and linkage to scan
data using NHS numbers was co-ordinated by the NHS
Wales Informatics Service (NWIS) (work completed during
2012 and 2013). All baseline questionnaires and ultrasound
data that were collected on the paper forms were entered
on a database by Screening Services Wales and uploaded to
NWIS to be linked to the other study datasets.
Statistical analysis
We will calculate study recruitment rates for each hospital
and Health Board. Socio-demographic characteristics (age
at pregnancy, employment status, cigarette smoking, alco-
hol use and the Welsh Index of Multiple Deprivation) and
pregnancy outcomes of women recruited to the study will
be described. Characteristics of women recruited to the
study will be compared with data routinely reported for
pregnant women in Wales, to assess how representative
the sample is of the general population.
We will calculate the reported prevalence of each
marker as a proportion of the number of pregnant
women with singleton pregnancies with scan data. We
will also report the prevalence of validated markers (de-
fined as markers confirmed by the expert panel). 95%
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be estimated using Bayesian methods in Winbugs, to ac-
count for the two-stage sampling process (the availability
of the images for review and the proportion of markers
reviewed that were confirmed). We will describe the
variation in prevalence of validated markers by NHS
hospital and Health Board as well as by maternal socio-
demographic and clinical characteristics. Unadjusted risk
ratios with 95% CI will be calculated to estimate the risk
of the adverse pregnancy outcomes in the presence of a
validated marker compared with no marker, and in the
presence of two or more markers compared with no
marker. Odds ratios, adjusted for maternal age and
deprivation score, will be calculated using logistic regres-
sion models if there is evidence of confounding by these
variables. Data will be analysed using Stata version 13.0.
Discussion
This is a large prospective population-based study designed
to estimate the prevalence of markers in a cohort of preg-
nant women and investigate associations with abnormal
pregnancy outcomes. Quantifying these markers and asses-
sing their significance is important as it will inform preg-
nancy management and parental counselling. The study
addresses the criticism that many previous studies have not
described their populations well and may not have included
“all-risk” women [4]. This work has established a cohort of
babies for longer-term follow-up to further explore associa-
tions between specific markers and child health outcomes,
which are currently poorly understood [3].
The study takes advantage of an electronic information
system for the collection of radiological data that was re-
cently implemented in parts of Wales. This allows for the
linkage of these data to high-quality population-based reg-
isters of pregnancy outcomes, congenital anomalies, and
stillbirths. A major strength of this study is that we asked
pregnant women at the time of recruitment for permis-
sion to access data that is routinely collected about the
health of their baby to facilitate follow-up studies investi-
gating health outcomes associated with markers detected
at the 18-20 week anomaly scan. This provides some flexi-
bility in the design of future follow-up studies, allowing us
to utilise the wealth of health data that is routinely col-
lected in a cost-effective way. For example, using record
linkage to routinely collected healthcare datasets we could
establish a future e-cohort study to explore whether babies
with a renal marker detected during pregnancy have a
higher risk of urinary tract infections or hospital admis-
sions for renal disease during childhood, compared to ba-
bies without a marker. This information is vital for
pregnant women, families and clinicians to facilitate the
development of appropriate clinical guidelines and care
pathways during pregnancy and after birth, including the
appropriate use of medical interventions and treatment.Additional files
Additional file 1: The consent form.
Additional file 2: The patient information leaflet.
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